A citation-based method for searching scientific literature

Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph. Diabetes Care 2018
Times Cited: 79







List of co-cited articles
491 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Brian Zambrowicz, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Kristi A Boehm, Dennis Ruff, David Powell, Arthur Sands. Clin Ther 2013
45
8


Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
David G Marrero, John Crean, Bei Zhang, Terrie Kellmeyer, Maurice Gloster, Kathrin Herrmann, Richard Rubin, Naomi Fineberg, Orville Kolterman. Diabetes Care 2007
32
12

Adjunctive Treatments for Type 1 Diabetes.
David M Nathan. N Engl J Med 2017
8
50

Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions.
David M Nathan, Margaret Bayless, Patricia Cleary, Saul Genuth, Rose Gubitosi-Klug, John M Lachin, Gayle Lorenzi, Bernard Zinman. Diabetes 2013
126
5

Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.
Shona J Livingstone, Daniel Levin, Helen C Looker, Robert S Lindsay, Sarah H Wild, Nicola Joss, Graham Leese, Peter Leslie, Rory J McCrimmon, Wendy Metcalfe,[...]. JAMA 2015
259
5

Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.
Julio Rosenstock, William T Cefalu, Pablo Lapuerta, Brian Zambrowicz, Ike Ogbaa, Phillip Banks, Arthur Sands. Diabetes Care 2015
46
8

Improved glycemic control in mice lacking Sglt1 and Sglt2.
David R Powell, Christopher M DaCosta, Jason Gay, Zhi-Ming Ding, Melinda Smith, Jennifer Greer, Deon Doree, Sabrina Jeter-Jones, Faika Mseeh, Lawrence A Rodriguez,[...]. Am J Physiol Endocrinol Metab 2013
92
5

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
198
5

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
John P Bilezikian, Nelson B Watts, Keith Usiskin, David Polidori, Albert Fung, Daniel Sullivan, Norm Rosenthal. J Clin Endocrinol Metab 2016
140
5

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
Nelson B Watts, John P Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gordon Law, Gary Meininger. J Clin Endocrinol Metab 2016
224
5

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetologia 2018
496
5


The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients.
Laurent Meyer, Philip Bohme, Irene Delbachian, Philippe Lehert, Nathalie Cugnardey, Pierre Drouin, Bruno Guerci. Diabetes Care 2002
58
6

Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
Nitesh D Kuhadiya, Sandeep Dhindsa, Husam Ghanim, Aditya Mehta, Antoine Makdissi, Manav Batra, Sartaj Sandhu, Jeanne Hejna, Kelly Green, Natalie Bellini,[...]. Diabetes Care 2016
44
9

Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk.
Ele Ferrannini, Anna Solini. Nat Rev Endocrinol 2017
5
80


Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
5


Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review.
Soulmaz Fazeli Farsani, Kimberly Brodovicz, Nima Soleymanlou, Jan Marquard, Erika Wissinger, Brett A Maiese. BMJ Open 2017
67
5

Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, Kristina I Rother. Diabetes Metab Res Rev 2017
74
5

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
204
5

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
347
5

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Giulia Ferrannini, Thomas Hach, Susanne Crowe, Arjun Sanghvi, Kevin D Hall, Ele Ferrannini. Diabetes Care 2015
171
5


Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study.
Christopher C Patterson, Valma Harjutsalo, Joachim Rosenbauer, Andreas Neu, Ondrej Cinek, Torild Skrivarhaug, Birgit Rami-Merhar, Gyula Soltesz, Jannet Svensson, Roger C Parslow,[...]. Diabetologia 2019
117
5

Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study.
Rose A Gubitosi-Klug, Barbara H Braffett, Neil H White, Robert S Sherwin, F John Service, John M Lachin, William V Tamborlane. Diabetes Care 2017
67
5

NICE guidance on dapagliflozin with insulin for type 1 diabetes.
Amanda I Adler, Sharlene Ting, Ross Dent, Nick Latimer. Lancet Diabetes Endocrinol 2019
6
66

The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
33
12

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
6


Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms.
Karen D Corbin, Kimberly A Driscoll, Richard E Pratley, Steven R Smith, David M Maahs, Elizabeth J Mayer-Davis. Endocr Rev 2018
59
6

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
Eiichi Araki, Hirotaka Watada, Yasuko Uchigata, Osamu Tomonaga, Hitomi Fujii, Hiroshi Ohashi, Tadashi Okabe, Michiko Asano, Fredrik Thoren, Hyosung Kim,[...]. Diabetes Obes Metab 2020
11
36

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona. Diabetes Obes Metab 2020
14
28


Type 1 diabetes in older adults: Comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries.
Ruth S Weinstock, Ingrid Schütz-Fuhrmann, Crystal G Connor, Julia M Hermann, David M Maahs, Morten Schütt, Shivani Agarwal, Sabine E Hofer, Roy W Beck, Reinhard W Holl. Diabetes Res Clin Pract 2016
25
12

SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
John R Petrie. Lancet Diabetes Endocrinol 2017
7
42

Phlorizin: a review.
Joel R L Ehrenkranz, Norman G Lewis, C Ronald Kahn, Jesse Roth. Diabetes Metab Res Rev 2005
497
3

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.
David R Powell, Deon Doree, Sabrina Jeter-Jones, Zhi-Ming Ding, Brian Zambrowicz, Arthur Sands. Diabetes Metab Syndr Obes 2015
14
21

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
L Rossetti, D Smith, G I Shulman, D Papachristou, R A DeFronzo. J Clin Invest 1987
678
3



Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.
Jenny E Blau, Viviana Bauman, Ellen M Conway, Paolo Piaggi, Mary F Walter, Elizabeth C Wright, Shanna Bernstein, Amber B Courville, Michael T Collins, Kristina I Rother,[...]. JCI Insight 2018
42
7


Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
R Ratner, F Whitehouse, M S Fineman, S Strobel, L Shen, D G Maggs, O G Kolterman, C Weyer. Exp Clin Endocrinol Diabetes 2005
40
7

The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
121
3



Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
S Sha, D Polidori, K Farrell, A Ghosh, J Natarajan, N Vaccaro, J Pinheiro, P Rothenberg, L Plum-Mörschel. Diabetes Obes Metab 2015
63
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.